What is Xencor, Inc. (XNCR) stock price today?

Xencor, Inc. (XNCR) is currently trading at $24.93, up 1.75% today.

What is XNCR P/E ratio?

Xencor, Inc.'s P/E ratio is -11.45. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is XNCR return on equity (ROE)?

Xencor, Inc.'s return on equity (ROE) is -28.66%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Xencor, Inc.'s market cap?

Xencor, Inc. has a market capitalization of $1.85B.

NASDAQ · Biotechnology

Xencor, Inc. (XNCR) Stock

$24.93 +1.75% NASDAQ: XNCR Healthcare

Valuation

Metric	Value
Price	$24.93
Market Cap	$1.85B
P/E Ratio	-11.45
P/B Ratio	3.74
P/S Ratio	17.54
EPS (TTM)	$-1.24
52-Week High	$30.61
52-Week Low	$10.38
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-28.66%
ROA	-22.53%
ROCE	-33.60%
Gross Margin	-140.48%
Operating Margin	-141.27%
Net Margin	-155.59%
Debt/Equity	0.13
Current Ratio	6.25

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$275.0M	$165.0M	$175.0M	$110.0M	$126.0M
Operating Profit	$44.0M	$-82.0M	$-132.0M	$-178.0M	$-178.0M
Net Profit	$83.0M	$-55.0M	$-133.0M	$-233.0M	$-92.0M
EPS	$1.37	$-0.93	$-2.08	$-3.58	$-1.24
Op Margin	15.9%	-50.1%	-75.8%	-161.5%	-141.3%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$838.0M	$846.0M	$953.0M	$952.0M	$875.0M
Total Liabilities	$105.0M	$119.0M	$284.0M	$278.0M	$240.0M
Cash	$143.0M	$54.0M	$54.0M	$41.0M	$54.0M
Borrowings	$34.0M	$60.0M	$83.0M	$232.0M	$188.0M

Latest News

VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone Exec Edge · Jul 2, 2026 Xencor (XNCR) Stock Draws Fresh Price Target Split As Pipeline Progress Meets Caution Simply Wall St. · Jun 14, 2026 Bi/Multispecific Drugs in Oncology Analytical Tool Featuring Top Developers - Amgen, Hoffmann-La Roche, J&J, Xencor, Biocytogen - Unlocking New Precision, Immune Activation, and Therapeutic Potential GlobeNewswire · May 12, 2026 These Analysts Think Xencor, Inc.'s (NASDAQ:XNCR) Sales Are Under Threat Simply Wall St. · May 8, 2026 Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates Zacks · May 6, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-17.0M	$24.0M	$-78.0M	$-202.0M	$-135.0M
Investing Cash Flow	$-62.0M	$-163.0M	$-129.0M	$-14.0M	$137.0M
Financing Cash Flow	$14.0M	$6.0M	$183.0M	$-4.0M	$-2.0M
Net Cash Flow	$-20.0M	$-90.0M	$0	$-13.0M	$13.0M
Free Cash Flow	$-33.0M	$-19.0M	$-96.0M	$-208.0M	$-138.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.16
EV / EBITDA	-15.07
FCF Yield	-11.31%
Quick Ratio	6.39
Interest Coverage	-7.98
Return 1Y	104.08%
Return 3Y	-19.36%
Return 5Y	-54.18%

Ownership

Insiders Held1.22%

Institutions Held115.39%

Institutions Float Held116.82%

Institutional Holder	Shares	Report Date
Blackrock Inc.	13,035,918	2026-03-31
Primecap Management Company	10,338,022	2026-03-31
BVF Inc.	7,133,720	2026-03-31
RTW Investments LP	6,777,461	2026-03-31
RA Capital Management, L.P.	4,897,237	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAPLApple Inc.	$332.41	-2.35%	38.93	$4.88T	0.32%
MSFTMicrosoft Corporation	$528.54	+1.13%	28.68	$3.92T	0.76%
GOOGLAlphabet Inc.	$351.97	+1.06%	16.94	$4.26T	0.26%
AMZNAmazon.com, Inc.	$258.71	+1.83%	19.82	$2.78T	0.00%
METAMeta Platforms, Inc.	$720.00	-0.12%	27.93	$1.83T	0.28%

About Xencor, Inc.

Xencor, Inc. is led by CEO Bassil I. Dahiyat, employs 250 people, headquartered in US, publicly traded since 2013.

Xencor, Inc. (XNCR) stock trades at $24.93 with a market capitalization of $1.85B. The stock is valued at a price-to-earnings (P/E) ratio of -11.45, price-to-book of 3.74, price-to-sales of 17.54. Over the past 52 weeks the stock has ranged between $10.38 and $30.61, and currently trades 18.6% below its 52-week high.

On profitability, Xencor, Inc. generates a return on equity (ROE) of -28.66%, return on capital employed of -33.60%, an operating margin of -141.27%, a net profit margin of -155.59%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1171.57 +0.17% JNJ Johnson & Johnson $259.05 +1.00% ABBV AbbVie Inc. $275.98 +1.30% MRK Merck & Company, Inc. Common Stock (new) $144.50 +1.49% UNH UnitedHealth Group Incorporated Common Stock (DE) $375.98 +1.36% NVS Novartis AG $143.67 +0.39% AZN AstraZeneca PLC $159.80 +0.64% TMO Thermo Fisher Scientific Inc $654.67 +0.41% AMGN Amgen Inc. $412.50 +1.24% GILD Gilead Sciences, Inc. $149.51 +1.64% ABT Abbott Laboratories $99.93 +1.46% NVO Novo Nordisk A/S $38.18 -0.21%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides